Clinical Trial Update: SOM230 Alone or in Combination With RAD001 in Patients With Medullary Thyroid Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating SOM230 alone or in combination with RAD001 for medullary thyroid carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Medullary Thyroid Carcinoma

Drugs mentioned

• RAD001 (everolimus)
• SOM230 (pasireotide)

Snippet

Sponsor: Federico II University | Conditions: Medullary Thyroid Cancer | Phase 2 | Status: COMPLETED